Clorox said net sales and volume each rose 27% and 26%, respectively, for the 3 months ended September 30, 2024, primarily due to lapping impacts from the August 2023 cyberattack.

1. 01

   Clorox said net sales and volume each rose 27% and 26%, respectively, for the 3 months ended September 30, 2024, primarily due to lapping impacts from the August 2023 cyberattack.

2. 02

   The company said its gross margin rose from 38.4% to 45.8%, a gain of 740 basis points, primarily driven by higher volume and cost savings. It said diluted EPS increased by $0.63 (371%), partially offset by the loss on the divestiture of the Better Health VMS business.

3. 03

   Clorox said net cash provided by operations for the 3 months was $221, up from $20 a year earlier. It said net cash provided by investing activities was $89, and net cash used by financing activities was $237. Amounts are presented as stated in the original filing.

4. 04

   The company said it completed the divestiture of its Better Health VMS business on September 10, 2024. Over the same 3 months, it repurchased 789 thousand shares at a cost of $107, compared with 0 shares repurchased in the year-earlier period.

Key figures

Quarter ended September 30, 2024

Revenue

$1.8B

Net income

$99M

EPS

$0.80

Gross profit

$807M

Operating cash flow

$221M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.